DVAX - ダイナバックス・テクノロジ―ズ （Dynavax Technologies Corporation） ダイナバックス・テクノロジ―ズDVAXのチャート
DVAXの企業情報
| symbol | DVAx |
|---|---|
| 会社名 | Dynavax Technologies Corp （ダイナバックス・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ダイナバクス・テクノロジーズ（Dynavax Technologies Corporation）は臨床段階の免疫療法会社である。同社はトール様受容体（TLR）刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。 ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン｢ヘプリサブ｣、自己免疫疾患治療用｢DV1179｣、喘息治療用｢AZD1419｣、癌免疫療法｢SD-101｣などがある。 Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. |
| 本社所在地 | 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA |
| 代表者氏名 | Arnold L. Oronsky アーノルドエルオロスキー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-848-5100 |
| 設立年月日 | 35278 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2004年 |
| 従業員数 | 170人 |
| url | www.dynavax.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dvax |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -115.44000 |
| 終値（lastsale） | 11.07 |
| 時価総額（marketcap） | 693154537.02 |
| 時価総額 | 時価総額（百万ドル） 700.66840 |
| 売上高 | 売上高（百万ドル） 1.49300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 584.39640 |
| 当期純利益 | 当期純利益（百万ドル） -127.95100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense). |
DVAXのテクニカル分析
DVAXのニュース
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results 2023/01/09 13:00:00 Investors Dynavax
Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and
Dynavax Technologies Corporation (DVAX) can beat the pack with these strategies 2022/12/23 13:16:00 US Post News
A share of Dynavax Technologies Corporation (NASDAQ:DVAX) closed at $11.42 per share on Thursday, up from $11.41 day before. While Dynavax Technologies Corporation has overperformed by 0.09%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -18.66%, with highs and lows ranging from $17.48 […]
The Dynavax Technologies Corporation (DVAX) had a good session last reading, didn’t it? 2022/12/05 16:16:00 US Post News
In Friday’s session, Dynavax Technologies Corporation (NASDAQ:DVAX) marked $12.72 per share, up from $12.54 in the previous session. While Dynavax Technologies Corporation has overperformed by 1.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -13.47%, with highs and lows ranging from $17.48 to […]
Clover, Dynavax COVID vaccine helps reduce household transmission of virus in trial 2022/11/30 11:13:17 Seeking Alpha
Clover Biopharmaceuticals reported additional data published in Clinical Infectious Diseases from a phase 2/3 of its vaccine SCB-2019 (CpG 1018/Alum) reducing the risk of…
Dynavax Technologies Corporation (DVAX) Rises From The Low: Could It Be A Catbird Seat? 2022/11/26 13:00:00 Stocks Register
Dynavax Technologies Corporation (NASDAQ:DVAX) concluded the trading at $12.34 on Friday, November 25, with a fall of -2.30% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $12.63 and 5Y monthly beta was reading 1.32 with its price kept floating in the … Dynavax Technologies Corporation (DVAX) Rises From The Low: Could It Be A Catbird Seat? Read More »
The Dynavax Technologies Corporation (DVAX) had a good session last reading, didn’t it? 2022/12/05 16:16:00 US Post News
In Friday’s session, Dynavax Technologies Corporation (NASDAQ:DVAX) marked $12.72 per share, up from $12.54 in the previous session. While Dynavax Technologies Corporation has overperformed by 1.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -13.47%, with highs and lows ranging from $17.48 to […]
Clover, Dynavax COVID vaccine helps reduce household transmission of virus in trial 2022/11/30 11:13:17 Seeking Alpha
Clover Biopharmaceuticals reported additional data published in Clinical Infectious Diseases from a phase 2/3 of its vaccine SCB-2019 (CpG 1018/Alum) reducing the risk of…
Dynavax Technologies Corporation (DVAX) Rises From The Low: Could It Be A Catbird Seat? 2022/11/26 13:00:00 Stocks Register
Dynavax Technologies Corporation (NASDAQ:DVAX) concluded the trading at $12.34 on Friday, November 25, with a fall of -2.30% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $12.63 and 5Y monthly beta was reading 1.32 with its price kept floating in the … Dynavax Technologies Corporation (DVAX) Rises From The Low: Could It Be A Catbird Seat? Read More »
Was anything positive for Dynavax Technologies Corporation (DVAX) stock last session? 2022/11/18 15:08:00 US Post News
Dynavax Technologies Corporation (NASDAQ:DVAX) closed Thursday at $13.29 per share, up from $12.96 a day earlier. While Dynavax Technologies Corporation has overperformed by 2.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -21.64%, with highs and lows ranging from $17.51 to $7.26, whereas […]
The Alphavaxers: Dynavax And Novavax — Facing The Shadow (DVAX) (NVAX) 2022/11/18 11:50:29 Seeking Alpha
The Alphavaxers Q3, 2022 earnings calls are in the book. The waning pandemic is taming guidances.
Can you now get a good deal on Dynavax Technologies Corporation’s shares? 2022/09/28 11:16:00 US Post News
Dynavax Technologies Corporation (NASDAQ:DVAX) closed Tuesday at $10.45 per share, up from $9.93 a day earlier. While Dynavax Technologies Corporation has overperformed by 5.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -43.48%, with highs and lows ranging from $21.39 to $7.26, whereas […]
Pleasing stocks: Dynavax Technologies Corporation (NASDAQ:DVAX 2.85%), JAKKS Pacific, Inc. (NASDAQ:JAKK 2.44%) 2022/09/14 23:57:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: Ø moving averages help traders define trend Ø recognize changes in trend. Now well have a look … The post Pleasing stocks: Dynavax Technologies Corporation (NASDAQ:DVAX 2.85%), JAKKS Pacific, Inc. (NASDAQ:JAKK 2.44%) appeared first on Stocks Equity .
These strategies will help Dynavax Technologies Corporation (DVAX) succeed 2022/09/07 15:48:00 US Post News
Dynavax Technologies Corporation (NASDAQ:DVAX) closed Tuesday at $10.75 per share, down from $11.21 a day earlier. While Dynavax Technologies Corporation has underperformed by -4.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DVAX fell by -39.20%, with highs and lows ranging from $21.39 to $7.26, whereas […]
Analysts Believe Dynavax Technologies Corporation (NASDAQ: DVAX)’S Shares May Fall -167.62% 2022/09/06 12:00:00 Stocks Register
Dynavax Technologies Corporation (NASDAQ:DVAX) price closed lower on Friday, September 02, dropping -3.28% below its previous close. A look at the daily price movement shows that the last close reads $11.59, with intraday deals fluctuated between $11.16 and $11.76. The company’s 5Y monthly beta was ticking 1.33 while its P/E ratio in the trailing 12-month … Analysts Believe Dynavax Technologies Corporation (NASDAQ: DVAX)’S Shares May Fall -167.62% Read More »
Is Dynavax Technologies Corporation (NASDAQ: DVAX) A Great Stock To Invest In? 2022/08/31 14:00:00 Stocks Register
Dynavax Technologies Corporation (NASDAQ:DVAX) traded at $11.34 at close of the session on Tuesday, 08/30/22, made an upward move of 3.09% on its previous day’s price. Looking at the stock we see that its previous close was $11.00 and the beta (5Y monthly) reads 1.33 with the day’s price range being $11.0407 – $11.37. The … Is Dynavax Technologies Corporation (NASDAQ: DVAX) A Great Stock To Invest In? Read More »